Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Charalambos Antoniades on AI-derived biomarkers that can predict heart attacks years before they happen

Professor Charalambos Antoniades is one of the researchers interviewed as part of the University's AI showcase, about his team's work developing technology that analyses coronory tomography (CT) angiograms to flag patients that are at risk of deadly heart attacks.

Heart attacks are usually caused by inflamed plaques in the coronary artery causing an abrupt blockage of blood getting to the heart. Professor Antoniades’ team has developed a technology, called the fat attenuation index (FAI), which detects the inflamed plaques prone to causing heart attacks by analysing CT images of the fat surrounding the arteries – something that is filtered out by any standard CT image analysis software.

Dr Antoniades said: "‘For the first time we have a set of biomarkers, derived from a routine test that is already used in everyday clinical practice, that measures what we call the “residual cardiovascular risk”, currently missed by all risk scores and non-invasive tests.

‘Knowing who is at increased risk for a heart attack could allow us to intervene early enough to prevent it. I expect these biomarkers to become an essential part of standard CT coronary angiography reporting in the coming years.’

Read the full article on the Oxford University website.

Read The Lancet paper on the Fat Attenuation Index.

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

Biotech spinout MiroBio acquired by Gilead Sciences for ~£332m

Co-founded by Simon Davis, MiroBio focuses on developing therapeutics for inflammatory diseases.

Professor Hugh Watkins wins £30 million research award to cure killer heart diseases

The British Heart Foundation award aims to help researchers rewrite DNA, in “defining moment” for cardiovascular medicine.

Six RDM research groups secure LEAF Sustainability Awards

The Laboratory Efficiency Assessment Framework (LEAF) aims to support research groups to embed sustainability into their work.

Ewa Gogola receives Wellcome Early Career Award

Dr Ewa Gogola from the Patel Group in the MRC Molecular Haematology Unit has been awarded funding by the Wellcome Trust for the project ‘DNA damage-induced hepatocyte polyploidisation- how it happens and what are its consequences?’